CLINICAL RESEARCH: ACUTE CORONARY SYNDROME
The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction
An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
John McMurray, MD, FACC*,*,
Scott Solomon, MD, FACC ,
Karen Pieper, MS ,
Shelby Reed, PhD,
Jean Rouleau, MD, FACC ,
Eric Velazquez, MD,
Harvey White, DSc, FACC||,
Jonathan Howlett, MD¶,
Karl Swedberg, MD, PhD#,
Aldo Maggioni, MD**,
Lars Køber, MD, PhD,
Frans Van de Werf, MD, FACC,
Rob Califf, MD, FACC and
Marc Pfeffer, MD, PhD, FACC
* Department of Cardiology, Western Infirmary, Glasgow, Scotland
Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
Duke University Medical Center, Durham, North Carolina
The Montreal Heart Institute, Montreal, Canada
|| Department of Cardiology, Green Lane Hospital, Auckland, New Zealand
¶ QE 11 Heart Function and Transplantation Clinic, Dalhousie University, Halifax, Nova Scotia, Canada
# Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden
** ANMCO Research Center, Florence, Italy
Department of Cardiology University of Copenhagen, Copenhagen, Denmark
Leuven Coordinating Center, Leuven, Belgium
Manuscript received June 22, 2005;
revised manuscript received August 22, 2005,
accepted September 8, 2005.
* Reprint requests and correspondence: Prof. John McMurray, Department of Cardiology, Level 4, Western Infirmary, Glasgow, G11 6NT, Scotland, United Kingdom. (Email: j.mcmurray{at}bio.gla.ac.uk).
OBJECTIVES: We attempted to compare the effect of an angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) on atherosclerotic events.
BACKGROUND: Angiotensin-converting enzyme inhibitors and ARBs interrupt the renin-angiotensin system by distinct mechanisms. It is not clear whether ARBs reduce atherosclerotic events such as myocardial infarction (MI) like ACE inhibitors. This evidence gap may reflect the nature of the studies conducted, to date. Placebo-controlled studies enrolled cohorts at low risk of atherosclerotic events (e.g., patients with chronic heart failure, most treated with an ACE inhibitor). One of the main active controlled trials was confounded by a blood pressure difference between treatments.
METHODS: We compared the effects of captopril, valsartan, and their combination on atherosclerotic events in 14,703 patients randomized in the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
RESULTS: The number of individuals adjudicated as having a fatal or non-fatal MI in the captopril group was 559 (total investigator reported events 798), 587 (796) in the valsartan group, and 554 (756) in the combination group; valsartan versus captopril, p = 0.651 (0.965); combination versus captopril, p = 0.187 (0.350). Overall, all atherosclerotic events examined occurred at a similar frequency in the captopril and valsartan groups.
CONCLUSIONS: Angiotensin receptor blockers appear to be as effective as ACE inhibitors in reducing atherosclerotic events, even when used in addition to other secondary preventive treatments. These data, although not conclusive, also support the hypothesis that adding an ARB to an ACE inhibitor may have a small additional anti-infarction effect, a possibility that needs to be prospectively tested.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | ARB = angiotensin receptor blocker | | CEC = Clinical End Points Committee | | CHF = chronic heart failure | | MI = myocardial infarction | | ONTARGET = ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint trial | | RAAS = renin-angiotensin system | | SAVE = Survival And Ventricular Enlargement study | | VALIANT = Valsartan in Acute Myocardial Infarction Trial | | VALUE = Valsartan Antihypertensive Long-term Use Evaluation trial |
|
This article has been cited by other articles:
|
|
|
|
 
M. Frimodt-Moller, A. Hoj Nielsen, S. Strandgaard, and A.-L. Kamper
Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease
Nephrol. Dial. Transplant.,
November 9, 2009;
(2009)
gfp547v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Divchev, C. Grothusen, M. Luchtefeld, M. Thoenes, F. Onono, R. Koch, H. Drexler, and B. Schieffer
Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease
Eur. Heart J.,
August 2, 2008;
29(16):
1956 - 1965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Werner and M. Bohm
Review: The therapeutic role of RAS blockade in chronic heart failure
Therapeutic Advances in Cardiovascular Disease,
June 1, 2008;
2(3):
167 - 177.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, M. J. Quon, Y. Lee, S. H. Han, J. Y. Ahn, W.-J. Chung, J.-a Kim, and E. K. Shin
Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients
Eur. Heart J.,
June 2, 2007;
28(12):
1440 - 1447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Iekushi, Y. Taniyama, J. Azuma, N. Katsuragi, N. Dosaka, F. Sanada, N. Koibuchi, K. Nagao, T. Ogihara, and R. Morishita
Novel Mechanisms of Valsartan on the Treatment of Acute Myocardial Infarction Through Inhibition of the Antiadhesion Molecule Periostin
Hypertension,
June 1, 2007;
49(6):
1409 - 1414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bangalore and F. H. Messerli
Of Statistical Significance: "Trends" Toward Significance and Optimism Bias
J. Am. Coll. Cardiol.,
October 3, 2006;
48(7):
1471 - 1471.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J.V. McMurray, R. M. Califf, and M. A. Pfeffer
Reply
J. Am. Coll. Cardiol.,
October 3, 2006;
48(7):
1471 - 1471.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Strauss and A. S. Hall
Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox
Circulation,
August 22, 2006;
114(8):
838 - 854.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T. Tsuyuki and M. A. McDonald
Response to Tsuyuki and McDonald
Circulation,
August 22, 2006;
114(8):
855 - 860.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Med.,
August 1, 2006;
11(4):
127 - 128.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Strauss, E. Lonn, and S. Verma
Angiotensin-II receptor blockers and coronary artery disease: 'presumed innocents': reply
Eur. Heart J.,
June 2, 2006;
27(12):
1507 - 1508.
[Full Text]
[PDF]
|
|
|
|
